Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria

F P Mockenhaupt1, J P Cramer, L Hamann

  • 1Institute of Tropical Medicine Berlin, Charité-Universitätsmedizin Berlin, Spandauer Damm 130, 14050 Berlin, Germany.

Insights

Genetic variations in Toll-like Receptor 4 (TLR4) increase the risk of severe malaria in children. Specific TLR4 polymorphisms, Asp299Gly and Thr399Ile, were significantly more frequent in severe malaria patients, highlighting TLR4

Area of Science:

  • Immunology
  • Genetics
  • Infectious Diseases

Background:

  • Malaria remains a major global health threat, causing over a million deaths annually.
  • Genetic factors significantly influence malaria susceptibility and severity.
  • Toll-like receptors (TLRs) are implicated in recognizing Plasmodium falciparum components and mediating host responses.

Purpose of the Study:

  • To investigate the association between polymorphisms in Toll-like Receptor (TLR)-2, TLR-4, and TLR-9 and susceptibility to severe malaria in Ghanaian children.
  • To identify genetic host factors contributing to malaria pathogenesis.

Main Methods:

  • A case-control study was conducted with 870 Ghanaian children.
  • Genotyping was performed for polymorphisms in TLR-2, TLR-4, and TLR-9.
  • Statistical analysis was used to compare allele frequencies between severe malaria cases and healthy controls.

Main Results:

  • TLR-2 variants common in other populations were absent; a rare signaling-impairing mutation (Leu658Pro) was identified.
  • No significant polymorphisms were found in the TLR-9/interleukin-1 receptor domain, and promoter polymorphisms showed no clear malaria association.
  • The TLR-4-Asp299Gly variant was more frequent in severe malaria patients (24.1%) than controls (17.6%), conferring a 1.5-fold increased risk.
  • The TLR-4-Thr399Ile variant was also more frequent in patients (6.2%) than controls (2.4%), conferring a 2.6-fold increased risk.

Conclusions:

  • TLR-4 polymorphisms are associated with increased risk and manifestation of severe malaria in Ghanaian children.
  • TLR4-mediated immune responses likely play a role in malaria pathogenesis.
  • Further research is needed to fully elucidate the complex interplay between TLRs and malaria.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...